JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Su, Y.-F.
Right arrow Articles by Chang, K.-J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Su, Y.-F.
Right arrow Articles by Chang, K.-J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ALFENTANIL
*NALTREXONE

Vol. 287, Issue 3, 815-823, December 1998

Delta-Opioid Ligands Reverse Alfentanil-Induced Respiratory Depression but Not Antinociception1

Ying-Fu Su, Robert W. McNutt and Kwen-Jen Chang

Departments of Anesthesiology and Pharmacology (Y.-F.S., K.-J.C.), Duke University Medical Center, Durham, Division of Chemistry (R.W.M.), Glaxo Wellcome Co., Research Triangle Park, and Delta Pharmaceuticals, Inc. (K.-J.C.), Research Triangle Park, North Carolina

Evidence suggests both opioid mu and delta receptors may participate in the regulation of respiration at different central nervous system sites. In the past, the overlapping receptor specificity of various opioid drugs has made it difficult to dissect the receptor subtype-specific activities involved in respiratory regulation. The new family of delta receptor selective agents such as cyclic[D-Pen2,5]enkephalin, deltorphins, (+)-4-((alpha -R)-alpha -((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N,N-diethylbenzamide, naltrindole and H-Tyr-Tic(psi )[CH2NH]Phe-Phe-OH have now made it feasible to more clearly define the role of delta receptors in respiratory control. In a series of experiments we observed that systemic infusion of rats with the highly mu receptor-specific opioid alfentanil induced antinociception and hypercapnia, and both of these effects were antagonized by the mu antagonist D-Phe-Cys-Tyr-Orn-Thr-Pen-Thr-NH2. However, peripheral administration of the delta receptor antagonist naltrindole reverses the hypercapnia but not the antinociceptive activity of alfentanil. This differential effect of naltrindole on antinociception and hypercapnia could also be produced with the delta agonist (+)-4-((alpha -R)-alpha -((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N,N-diethylbenzamide. In addition, intracerebroventricular delivery of a number of peptide delta ligands cyclic[D-Pen2,5]enkephalin, deltorpnin II and H-Tyr-Tic(psi )[CH2NH]Phe-Phe-OH also produced the same differential reversal of hypercapnia without affecting antinociception. Thus, both the traditional delta agonists and antagonists are able to reverse the alfentanil-induced hypercapnia without affecting antinociception. The reversal of alfentanil-induced hypercapnia by these delta ligands was antagonized by a novel synthetic delta antagonist cis-4-(alpha -(4-((Z)-2-butenyl)-3,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N,N-diethylbenzamide. We propose that in this experimental respiration model, the delta antagonists naltrindole and H-Tyr-Tic(psi )[CH2NH]Phe-Phe-OH behave like delta agonists with low but sufficient intrinsic activities to reverse alfentanil-induced hypercapnia in rats. The results suggest that a function of the delta receptor is to modulate or counteract the respiratory depression induced by the mu receptor.

0022-3565/98/2873-0815$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
A. Yassen, J. Kan, E. Olofsen, E. Suidgeest, A. Dahan, and M. Danhof
Pharmacokinetic-Pharmacodynamic Modeling of the Respiratory Depressant Effect of Norbuprenorphine in Rats
J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 598 - 607.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
E. E. Codd, J. R. Carson, R. W. Colburn, S. L. Dax, D. Desai-Krieger, R. P. Martinez, L. A. McKown, L. A. Neilson, P. M. Pitis, P. L. Stahle, et al.
The Novel, Orally Active, Delta Opioid RWJ-394674 Is Biotransformed to the Potent Mu Opioid RWJ-413216
J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 1273 - 1279.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
G. W. Stevenson, J. E. Folk, K. C. Rice, and S. S. Negus
Interactions between {delta} and {micro} Opioid Agonists in Assays of Schedule-Controlled Responding, Thermal Nociception, Drug Self-Administration, and Drug versus Food Choice in Rhesus Monkeys: Studies with SNC80 [(+)-4-[({alpha}R)-{alpha}-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide] and Heroin
J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 221 - 231.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
P. J. Gengo, H. O. Pettit, S. J. O'Neill, Y. F. Su, R. McNutt, and K.-J. Chang
DPI-3290 [(+)-3-(({alpha}-R)-{alpha}-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide]. II. A Mixed Opioid Agonist with Potent Antinociceptive Activity and Limited Effects on Respiratory Function
J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 1227 - 1233.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
P. J. Gengo, H. O. Pettit, S. J. O'Neill, K. Wei, R. McNutt, M. J. Bishop, and K.-J. Chang
DPI-3290 [(+)-3-(({alpha}-R)-{alpha}-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide]. I. A Mixed Opioid Agonist with Potent Antinociceptive Activity
J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 1221 - 1226.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
P. Petrillo, O. Angelici, S. Bingham, G. Ficalora, M. Garnier, P. F. Zaratin, G. Petrone, O. Pozzi, M. Sbacchi, T. O. Stean, et al.
Evidence for a Selective Role of the {delta}-Opioid Agonist [8R-(4bS*,8a{alpha},8a{beta},12b{beta})]7,10-Dimethyl-1-methoxy-11-(2-methylpropyl)oxycarbonyl 5,6,7,8,12,12b-hexahydro-(9H)-4,8-methanobenzofuro[3,2-e]pyrrolo[2,3-g]isoquinoline Hydrochloride (SB-235863) in Blocking Hyperalgesia Associated with Inflammatory and Neuropathic Pain Responses
J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 1079 - 1089.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
G. W. Stevenson, J. E. Folk, D. C. Linsenmayer, K. C. Rice, and S. S. Negus
Opioid Interactions in Rhesus Monkeys: Effects of {delta} + {micro} and {delta} + {kappa} Agonists on Schedule-Controlled Responding and Thermal Nociception
J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 1054 - 1064.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. L. Wells, J. L. Bartlett, S. Ananthan, and E. J. Bilsky
In Vivo Pharmacological Characterization of SoRI 9409, a Nonpeptidic Opioid {micro}-Agonist/delta -Antagonist That Produces Limited Antinociceptive Tolerance and Attenuates Morphine Physical Dependence
J. Pharmacol. Exp. Ther., April 12, 2001; 297(2): 597 - 605.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics.